Skip to main content
. 2021 Jul 12;10(7):48. doi: 10.1038/s41389-021-00339-6

Fig. 2. The DOT1L inhibitor EPZ-5676 inhibits H3K79me2 mark in ovarian cancer cell lines.

Fig. 2

A Schematics showing how DOT1L regulates the H3K79 dimethyl mark and how the pharmacological inhibition of DOT1L via EPZ-5676 leads to suppression of the mark. B EPZ-5676 inhibitor structure and formula. C EPZ-5676 inhibitor studies in clinical trials as reported on ClinicalTrials.gov. D The common names, synonyms, and disease associations of the ovarian cancer cell lines used in this study. E The indicated ovarian cancer cell lines were treated with various concentrations of the DOT1L inhibitor EPZ-5676 for 48 h. H3K79 dimethyl marks were then measured. Histone H3 and ACTINB proteins were measured as loading controls.